Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 96

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 96
---
515,265 Ordinary Shares upon the automatic conversion of the 2,515,265 Preferred     
 Shares issued and outstanding as of the date hereof, which will automatically convert upon the completion of this offering at a 1:1   
 ratio; (ii) the issuance of 609,888 Ordinary Shares upon the automatic conversion of the $900,000 outstanding principal of 2020 CLAs, 
 which will occur upon the completion of this offering; (iii) the issuance of 553,640 Ordinary Shares upon the automatic conversion    
 of the $450,000 outstanding principal of 2024 CLAs, which will occur upon the completion of this offering; and (iv) the receipt of    
 a Bridge Loan in the total amount of $350,000.                                                                                        |

| ● | on a pro forma as adjusted basis to give further effect to: (i) the sale of                                                          
 909,090 Ordinary Shares in this offering at an initial public offering price of $11.00 per Ordinary Share, which is the              
 midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions   
 and estimated offering expenses payable by us; (ii) repayment of the Bridge Loan in the total amount of $350,000 plus accrued        
 interest and an aggregate risk premium in the amount of $105,000; (iii) the repayment of the 2024 Loan Agreements (as defined below) 
 in the total amount of $150,000 plus accrued interest and an aggregate risk premium in the amount of $45,000; and (iv) the repayment 
 of the December 2024 Loan (as defined below) in the total amount of $117,000 plus accrued interest and an aggregate risk premium of  
 approximately $35,000, as if such events had occurred on June 30, 2024.                                                              |

The pro forma as adjusted
information set forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other
terms of this offering determined at pricing.

You should read this table
in conjunction with the sections titled “Use of Proceeds”, “Selected Financial Data”, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included
elsewhere in this prospectus.

|                                 |     | As of June 30, 2024 |         |   |     |           |       |   |     |                |       |
|:--------------------------------|